Volume 28, Issue 2 - Generics and biosimilars

Medical writing for generics throughout the life cycle

Author: Sandra Götsch -Schmidt

Abstract

Download the full article

References

1. European Medicines Agency. Generic and hybrid medicines. [cited 2019 Mar 07] Available from: Available from: https://www.ema.europa. eu/en/human-regulatory/marketingauthorisation/ generic-hybrid-medicines.
2. Fusier I, Tollier C, Husson MC. Medicines containing pharmaceutical excipients with known effects: a French review. Pharm World Sci. 2003;25(4):152 5.
3. Rowe RC, Sheskey PJ, Weller PJ. (2003). Handbook of pharmaceutical excipients. London: Pharmaceutical Press.
4. Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668). EMA/CHMP/302620/2017 Corr. 1. European Medicines Agency; 2018 Nov 19 [cited 2019 Mar 09]. Available from: Available from: https://www.ema.europa.eu/en/annexeuropean- commission-guidelineexcipients- labelling-package-leafletmedicinal- products-human.
5. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. Official Journal L- 311,28/11/2004, p. 67-128. [cited 2019 Feb 08]. Available from: Available from: https://eurlex. europa.eu/legal-content/en/ALL/ ?uri= CELEX%3A32001L0083.
6. Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/ 1401/98 Rev. 1/ Corr. European Medicines Agency; 2010 Jan 20 [cited 2019 Mar 06]. Available from: Available from: https://www.ema.europa. eu/en/investigation-bioequivalence.
7. van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS One. 2011;6(8):e23611.
8. Al Ameri MN, Nayuni N, Anil Kumar KG, Perrett D, Tucker A, Johnston A. The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing. Results Pharma Sci. 2011;2:1 8.
9. Davit BM, Kanfer I, Tsang YC, Cardot JM. Götsch-Schmidt –Medical writing for generics throughout the life cycle Medical writing for generics poses its own challenges and requires some specialist knowledge. 44 | June 2019 Medical Writing | Volume 28 Number 2 Medical writing for generics throughout the life cycle – Götsch-Schmidt BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements. AAPS J. 2016;18(3):612 8
10. ICH guideline M9 on biopharmaceutics classification system based biowaivers, step 2b. EMA/CHMP/ICH/493213/2018. European Medicines Agency; 2018 Aug 06. [cited 2019 Mar 07]. Available from: Available from: https://www.ema.europa.eu/en/ich-m9- biopharmaceutics-classification-systembased- biowaivers
11. Stuart MC. The Complete Guide to Medical Writing. London: Pharmaceutical Press; 2007.
12. Generics and Biosimilars Initiative. EU guidelines for generics Posted 08/10/2010. Last update: 18 November 2011. [cited 2019 Mar 07]. Available at: Available from: http://www.gabionline.net/Guidelines/ EU-guidelines-for-generics
13. EudraLex Notice to Applicants Volume 2B - Presentation and content of the dossier. Edition May 2008 [cited 2019 Mar 07]. Available from: Available from: https://ec.europa.eu/ health/documents/ eudralex/vol-2_de.
14. QRD general principles regarding the SmPC information for a generic/hybrid/biosimilar product. EMA/627621/2011 rev.1. European Medicines Agency; 2018 Jun 18. [cited 2019 Mar 07]. Available from: Available from: https://www.ema.europa.eu/en/ human-regulatory/marketingauthorisation/ product-information/ product-information-reference-documentsguidelines.
15. Guideline on good pharmacovigilance practices (GVP), Module V – Risk management systems (Rev 2). EMA/838713/2017 Rev 2. European Medicines Agency; 2017 Mar 28 [cited 2019 Mar 06]. Available from: Available from: https://www.ema.europa.eu/en/humanregulatory/ post-authorisation/ pharmacovigilance/goodpharmacovigilance- practices#final-gvpmodules- section.
16. Appendix IV of the Guideline on the Investigation on Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of Biopharmaceutical and Bioanalytical Data in Module 2.7.1. EMA/CHMP/600958/2010/Corr.* Committee of Medicines for Human Use (CHMP); 17 November 2011. [cited 2019 Mar 08]. Available from: Available from: https://www.ema.europa.eu/en/appendixiv- guideline-investigation-bioequivalencepresentation- biopharmaceutical-bio analytical-data.
17. Directive 2010/84/EU of the European Union Parliament and of the Council of 15 December 2010 amending, as regards to pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. [cited 2019 Feb 08]. Available from: Available from: https:// eur-lex.europa.eu/legal-content/EN/ TXT/?qid=1549629653590&uri=CELEX: 32010L0084.
18. Guideline on good pharmacovigilance practices (GVP), Module VII – Periodic safety update report (Rev 1). EMA/816292/2011 Rev 1. European Medicines Agency; 2013 Dec 09 [cited 2019 Mar 06]. Available from: Available from: https://www.ema.europa. eu/en/humanregulatory/ post-authorisation/ pharmacovigilance/goodpharmacovigilance- practices#final-gvpmodules- section
19. CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures. CMDh/004/2005/Rev.16. February 2018 [cited 2019 Mar 08]. Available from: Available from: http://www.hma.eu/95.html.
20. Bundesamt für Sicherheit im Gesundheitswesen (Austrian Federal Office for Safety in Health Care). FAQs about Pharmacovigilance, question 1.2 PHV documents for renewal procedure. [cited 2019 Mar 08]. Available from: Available from: https://www.basg.gv.at/en/pharmacovigil ance/faqs-about-pharmacovigilance/.